Telemedicine Buprenorphine for Opioid Use Disorder
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a telemedicine approach to treating Opioid Use Disorder (OUD) with buprenorphine, a medication that helps manage withdrawal and cravings. The goal is to determine if a virtual platform can effectively reach individuals who might not otherwise receive help, particularly those needing culturally specific support. Individuals with OUD who are starting or have recently started buprenorphine treatment, and who can speak and understand English, may be suitable for this study. As a Phase 1 trial, the research focuses on understanding how the treatment works in people, offering participants the opportunity to contribute to groundbreaking insights.
Do I have to stop taking my current medications for the trial?
The trial information does not specify if you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
What prior data suggests that this telemedicine treatment is safe for opioid use disorder?
Research has shown that starting buprenorphine treatment for opioid use disorder through telehealth can help patients remain in treatment longer. For instance, in Ohio, 32% of patients who began this treatment via telehealth continued for 90 consecutive days, compared to 28% who started in person. Another study found that telemedicine can effectively substitute for in-person visits in maintaining patient engagement in treatment programs.
While these studies mainly focus on telehealth's effectiveness in retaining patients, they also suggest that this method is generally safe and well-tolerated. Since this trial is in an early stage, it primarily examines safety. Early trials often assess a treatment's safety before evaluating its effectiveness. Buprenorphine is already used for opioid use disorder, so its safety is somewhat established. However, delivering it via telemedicine is new. So far, this approach seems promising for keeping patients engaged without major safety concerns.12345Why are researchers excited about this trial?
Researchers are excited about telemedicine buprenorphine treatment for opioid use disorder because it offers a unique delivery method that could significantly increase access to care. Unlike traditional in-person treatments, which often require regular visits to a healthcare provider, this method allows patients to receive care remotely. This is particularly important for individuals in rural or underserved areas who may struggle to access regular treatment. Additionally, telemedicine can reduce the stigma some patients feel when seeking help, making it a more appealing option for those who are hesitant to visit a clinic in person.
What evidence suggests that telemedicine buprenorphine treatment might be an effective treatment for opioid use disorder?
Research has shown that telemedicine for buprenorphine treatment effectively helps people with Opioid Use Disorder (OUD). Buprenorphine, an FDA-approved medication, reduces cravings and withdrawal symptoms. Studies indicate that starting buprenorphine treatment through telehealth increases the likelihood of staying in treatment longer. Telehealth also simplifies access to care, especially for those who find it difficult to travel to a clinic. Overall, telemedicine offers a promising way to support people with OUD.678910
Who Is on the Research Team?
Andrea Baron, MPH
Principal Investigator
Boulder Care
Are You a Good Fit for This Trial?
This trial is for individuals with a history of Opioid Use Disorder who are starting or have recently started treatment with buprenorphine. Participants must speak and understand English and plan to stay in a Boulder Care-affiliated state for at least the next year. Those with untreated mental or medical health conditions that could interfere with participation, or an allergy to buprenorphine, cannot join.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive telehealth-based treatment for Opioid Use Disorder
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Telemedicine Buprenorphine Treatment
Find a Clinic Near You
Who Is Running the Clinical Trial?
Boulder Care
Lead Sponsor
National Institute on Drug Abuse (NIDA)
Collaborator